Results of a meta-analysis reveal significant reductions in blood pressure and heart rate.
In their meta-analysis of grape seed extract and heart health factors, researchers from the University of Connecticut and Yale University say that grape seed extract appears to lower blood pressure and heart rate in human subjects. The work has been published in the Journal of the American Dietetic Association.
Database searches on trials investigating grape seed extract supplementation and heart health factors including blood pressure, heart rate, and cholesterol yielded nine studies (390 subjects) fit for meta-analysis.
Results of the meta-analysis revealed significant reductions in blood pressure (-1.54 mm Hg) and heart rate (-1.42 bpm). These changes may seem small, but lead author Craig Coleman of the University of Connecticut stresses that a little change can go a long way:
The level of systolic blood pressure reduction is very modest in comparison to reductions seen with prescription antihypertensive drugs. However, this modest effect may still be noteworthy on a population basis. It has been estimated that every 3 mm Hg reduction in systolic blood pressure could reduce the risk of all-cause mortality by 4%, mortality after stroke by 8% and mortality after coronary artery disease by 5%.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.